Dr Eli Avisar (@dr_avisar) 's Twitter Profile
Dr Eli Avisar

@dr_avisar

Prof Surgery @UMiami
Fellow @AmCollSurgeons
Member @SocSurgOncology & @ASBrS Director @JMH Breast Ctr Director breast fellowship @UM/JMH
Ski/Pilot/Spiritual

ID: 857652378530717697

calendar_today27-04-2017 17:47:16

145 Tweet

126 Followers

26 Following

Dr Eli Avisar (@dr_avisar) 's Twitter Profile Photo

Watch as Dr. Eli Avisar, breast surgical #oncologist and #lymphedema specialist, lists three things you didn’t know about lymphedema. | Instagram instagram.com/reel/Cyy_A8QrP…

Sylvester Comprehensive Cancer Center (@sylvestercancer) 's Twitter Profile Photo

Join us in congratulating Dr. Anshumi Desai as one of the recipients of Panchi’s Postdoctoral Prize. 🙌🎉 “This #award signifies the strength of our collaborative #team, guided by inspiring #mentors and supported by dedicated colleagues and #medical #students,” said Dr. Desai.

Join us in congratulating Dr. <a href="/AnshumiDesai/">Anshumi Desai</a> as one of the recipients of Panchi’s Postdoctoral Prize. 🙌🎉

“This #award signifies the strength of our collaborative #team, guided by inspiring #mentors and supported by dedicated colleagues and #medical #students,” said Dr. Desai.
Dr Eli Avisar (@dr_avisar) 's Twitter Profile Photo

TARGIT IORT Under Threat, Again Recently we were challenged by American Society of Therapeutic Radiation Oncology proposing a change in policy that could lead to the loss of insurance coverage for Targeted Intraoperative Radiotherapy (TARGIT) for early-stage breast cancer.

Dr Eli Avisar (@dr_avisar) 's Twitter Profile Photo

We are now facing the same challenge from the American Society of Breast Surgeons which at this moment is considering adopting a policy that will likely lead to many women losing access to Targeted Intraoperative Radiotherapy.

Dr Eli Avisar (@dr_avisar) 's Twitter Profile Photo

Although breast surgeons have generally been among the strongest advocates for IORT, the leaders of the American Society of Breast Surgeons are likely being influenced by their radiation oncology colleagues who have a vested financial interest in opposing IORT.

Dr Eli Avisar (@dr_avisar) 's Twitter Profile Photo

The bottom line (literally!) is that radiation oncologists make much less money doing IORT compared to traditional radiation. Although they make a lot of fuss about a 2-4% difference in IORT effectiveness compared to traditional radiation, the real elephant in the room is $$$.

Dr Eli Avisar (@dr_avisar) 's Twitter Profile Photo

Here's why targeted IORT needs to be protected: IORT is a single dose radiation treatment administered in &lt; 30 minutes at the time of lumpectomy. It has less radiation exposure to skin, heart and lungs,eliminates the financial burden of daily treatments, with superior cosmesis

Dr Eli Avisar (@dr_avisar) 's Twitter Profile Photo

Critics of TARGIT complaint that targeted IORT has a higher recurrence rate compared to traditional whole breast radiation. Although some forms of IORT have been shown to have a 2-4% higher recurrence rate compared to whole breast radiation, that is NOT the case for TARGIT.

Dr Eli Avisar (@dr_avisar) 's Twitter Profile Photo

Furthermore this stance completely disregards patient choice in healthcare decision-making How can you help? Let the American Society of Breast Surgeons know your opinion lnkd.in/e4NYyBzB Comments are due by end of day June 9th, 2025. Sorry for the short timeline.